For the quarter ending 2026-03-31, TDAC has $183,346,585 in assets. $6,898,585 in debts. $24,630 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 24,630 | 29,787 | 47,150 | 35,255 |
| Prepaid expenses | 50,686 | 9,678 | 33,432 | 120,822 |
| Total current assets | 75,316 | 39,465 | 80,582 | 156,077 |
| Marketable securities held in trust account | 183,271,269 | 181,657,311 | 179,899,077 | 178,025,297 |
| Total assets | 183,346,585 | 181,696,776 | 179,979,659 | 178,181,374 |
| Accounts payable and accrued expenses | 224,323 | 162,311 | 171,083 | 162,920 |
| Due to sponsor | 136,762 | 106,762 | 76,762 | 46,762 |
| Promissory note - related party | 500,000 | 200,000 | 100,000 | - |
| Accrued offering costs | - | 75,000 | 75,000 | 75,000 |
| Total current liabilities | 861,085 | 544,073 | 422,845 | 284,682 |
| Deferred underwriting fee | 6,037,500 | 6,037,500 | 6,037,500 | 6,037,500 |
| Total liabilities | 6,898,585 | 6,581,573 | 6,460,345 | 6,322,182 |
| Class a ordinary shares subject to possible redemption, 0.0001 par value 17,250,000 shares issued and outstanding at redemption value of 10.62 and 10.53 per share as of march 31, 2026 and december 31, 2025, respectively | 183,271,269 | 181,657,311 | 179,899,077 | 178,025,297 |
| Common stock-Classa Ordinary Shares Not Subject To Redemption | 0 | - | - | - |
| Common stock-Common Class B | 466 | 466 | 466 | 466 |
| Accumulated deficit | -6,823,735 | -6,542,574 | -6,380,229 | -6,166,571 |
| Total shareholders' deficit | -6,823,269 | -6,542,108 | -6,379,763 | -6,166,105 |
| Total liabilities, class a ordinary shares subject to possible redemption, and shareholders' deficit | 183,346,585 | 181,696,776 | 179,979,659 | 178,181,374 |
Translational Development Acquisition Corp. (TDAC)
Translational Development Acquisition Corp. (TDAC)